Antineoplastic immunoconjugates and immunotoxins

Research output: Contribution to journalArticle

Abstract

This paper discusses the scientific rationale, synthesis, therapeutic utility and clinical limitations of cancer chemotherapy with antineoplastic drugs or toxins covalently linked to monoclonal antibodies directed against tumor cell antigens. Chemical issues that must be considered when designing an effective antineoplastic immunoconjugate or immunotoxin (including purity, functional group suitability for conjugation, antigenic specificity, stability, solubility, potency and immunogenicity) are discussed. Synthetic strategies used in the gener ation of immunoconjugates and immunotoxins are presented, and the use of flexible spacer molecules as adjuncts to conjugation is described. The use of targeting antibodies conjugated to enzymes that selectively activate antineoplastic prodrugs on or near cancer cells (known as antibody-directed enzyme pro-drug therapy, or ADEPT) is also addressed. The paper ends with a brief discussion on the development of chimeric and humanized antibodies, which are designed to decrease the incidence of the human anti-mouse antibody (HAMA) response that is so often responsible for treatment failure with these targeted anticancer agents.

Original languageEnglish
Pages (from-to)197-204
Number of pages8
JournalAmerican Journal of Pharmaceutical Education
Volume64
Issue number2
StatePublished - 2000

Fingerprint

Immunoconjugates
Immunotoxins
Antineoplastic Agents
cancer
drug
Prodrugs
incidence
Antibodies, Monoclonal, Humanized
Drug Therapy
Antibodies
Neoplasm Antigens
Enzymes
Treatment Failure
Solubility
Antibody Formation
Epitopes
Anti-Idiotypic Antibodies
Neoplasms
Group
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Education

Cite this

Antineoplastic immunoconjugates and immunotoxins. / Roche, Victoria F.

In: American Journal of Pharmaceutical Education, Vol. 64, No. 2, 2000, p. 197-204.

Research output: Contribution to journalArticle

@article{eeaa187695bd4e6387b23fecf9032c95,
title = "Antineoplastic immunoconjugates and immunotoxins",
abstract = "This paper discusses the scientific rationale, synthesis, therapeutic utility and clinical limitations of cancer chemotherapy with antineoplastic drugs or toxins covalently linked to monoclonal antibodies directed against tumor cell antigens. Chemical issues that must be considered when designing an effective antineoplastic immunoconjugate or immunotoxin (including purity, functional group suitability for conjugation, antigenic specificity, stability, solubility, potency and immunogenicity) are discussed. Synthetic strategies used in the gener ation of immunoconjugates and immunotoxins are presented, and the use of flexible spacer molecules as adjuncts to conjugation is described. The use of targeting antibodies conjugated to enzymes that selectively activate antineoplastic prodrugs on or near cancer cells (known as antibody-directed enzyme pro-drug therapy, or ADEPT) is also addressed. The paper ends with a brief discussion on the development of chimeric and humanized antibodies, which are designed to decrease the incidence of the human anti-mouse antibody (HAMA) response that is so often responsible for treatment failure with these targeted anticancer agents.",
author = "Roche, {Victoria F.}",
year = "2000",
language = "English",
volume = "64",
pages = "197--204",
journal = "American Journal of Pharmaceutical Education",
issn = "0002-9459",
publisher = "American Association of Colleges of Pharmacy",
number = "2",

}

TY - JOUR

T1 - Antineoplastic immunoconjugates and immunotoxins

AU - Roche, Victoria F.

PY - 2000

Y1 - 2000

N2 - This paper discusses the scientific rationale, synthesis, therapeutic utility and clinical limitations of cancer chemotherapy with antineoplastic drugs or toxins covalently linked to monoclonal antibodies directed against tumor cell antigens. Chemical issues that must be considered when designing an effective antineoplastic immunoconjugate or immunotoxin (including purity, functional group suitability for conjugation, antigenic specificity, stability, solubility, potency and immunogenicity) are discussed. Synthetic strategies used in the gener ation of immunoconjugates and immunotoxins are presented, and the use of flexible spacer molecules as adjuncts to conjugation is described. The use of targeting antibodies conjugated to enzymes that selectively activate antineoplastic prodrugs on or near cancer cells (known as antibody-directed enzyme pro-drug therapy, or ADEPT) is also addressed. The paper ends with a brief discussion on the development of chimeric and humanized antibodies, which are designed to decrease the incidence of the human anti-mouse antibody (HAMA) response that is so often responsible for treatment failure with these targeted anticancer agents.

AB - This paper discusses the scientific rationale, synthesis, therapeutic utility and clinical limitations of cancer chemotherapy with antineoplastic drugs or toxins covalently linked to monoclonal antibodies directed against tumor cell antigens. Chemical issues that must be considered when designing an effective antineoplastic immunoconjugate or immunotoxin (including purity, functional group suitability for conjugation, antigenic specificity, stability, solubility, potency and immunogenicity) are discussed. Synthetic strategies used in the gener ation of immunoconjugates and immunotoxins are presented, and the use of flexible spacer molecules as adjuncts to conjugation is described. The use of targeting antibodies conjugated to enzymes that selectively activate antineoplastic prodrugs on or near cancer cells (known as antibody-directed enzyme pro-drug therapy, or ADEPT) is also addressed. The paper ends with a brief discussion on the development of chimeric and humanized antibodies, which are designed to decrease the incidence of the human anti-mouse antibody (HAMA) response that is so often responsible for treatment failure with these targeted anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=0039975652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0039975652&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 197

EP - 204

JO - American Journal of Pharmaceutical Education

JF - American Journal of Pharmaceutical Education

SN - 0002-9459

IS - 2

ER -